Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
14 Abril 2023 - 12:00AM
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial
Results and Operational Progress on April 19, 2023
Vivoryon Therapeutics N.V.
to Report
Full Year 2022
Financial Results and
Operational Progress on
April 19,
2023
Halle (Saale) / Munich,
Germany, April
14, 2023 -
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)
(Vivoryon), a clinical stage company focused on
the discovery and development of small molecule medicines to
modulate the activity and stability of pathologically altered
proteins, today announced that it will publish its financial
results for the full year 2022 and provide a corporate update on
Wednesday, April 19, 2023. The Company will host a conference call
and webcast open to the public. The report will be available for
download on the Company's website
(https://www.vivoryon.com/investors-news/financial-information/).Conference
call detailsDate: April 19, 2023Time: 03:00 pm CEST /
09:00 am EDTThe conference call will be available via phone and
webcast. The live audio webcast of the call will be available of
the Vivoryon website at:
https://www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/
To join the conference call via phone, participants may
pre-register and will receive dedicated dial-in details to easily
and quickly access the call via the following website:
https://register.vevent.com/register/BI4258c63704394e8283359d44ef59a7ea
It is suggested participants dial into the conference call 15
minutes prior to the scheduled start time to avoid any delays in
attendance.
###
About Vivoryon Therapeutics
N.V.Vivoryon is a clinical stage biotechnology company
focused on developing innovative small molecule-based medicines.
Driven by our passion for ground-breaking science and innovation,
we strive to change the lives of patients in need suffering from
severe diseases. We leverage our in-depth expertise in
understanding post-translational modifications to develop medicines
that modulate the activity and stability of proteins which are
altered in disease settings. Beyond our lead program,
varoglutamstat, which is in Phase 2 clinical development to treat
Alzheimer’s disease, we have established a solid pipeline of orally
available small molecule inhibitors for various indications
including cancer, inflammatory diseases and fibrosis.
www.vivoryon.com
Forward-Looking
StatementsThis press release includes forward-looking
statements, including, without limitation, those regarding the
business strategy, management plans and objectives for future
operations of the Vivoryon Therapeutics N.V. (the “Company”),
estimates and projections with respect to the market for the
Company’s products and forecasts and statements as to when the
Company’s products may be available. Words such as “anticipate,”
“believe,” “estimate,” “expect,” “forecast,” “intend,” “may,”
“plan,” “project,” “predict,” “should” and “will” and similar
expressions as they relate to the Company are intended to identify
such forward-looking statements. These forward-looking statements
are not guarantees of future performance; rather they are based on
the Management’s current expectations and assumptions about future
events and trends, the economy and other future conditions. The
forward-looking statements involve a number of known and unknown
risks and uncertainties. These risks and uncertainties and other
factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. Actual results,
performance or events may differ materially from those expressed or
implied in such forward-looking statements and from expectations.
As a result, no undue reliance should be placed on such
forward-looking statements. This press release does not contain
risk factors. Certain risk factors that may affect the Company’s
future financial results are discussed in the published annual
financial statements of the Company. This press release, including
any forward-looking statements, speaks only as of the date of this
press release. The Company does not assume any obligation to update
any information or forward-looking statements contained herein,
save for any information required to be disclosed by law. This
press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of the Company in
any jurisdiction.
For more information, please contact:
Investor ContactStern IRJulie SeidelTel: +1
212-698-8684Email: SternIR-Vivoryon@sternir.com
Media ContactTrophic CommunicationsValeria
FisherTel: +49 175 8041816Email: vivoryon@trophic.eu
Vivoryon Therapeut (EU:VVY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Vivoryon Therapeut (EU:VVY)
Gráfica de Acción Histórica
De May 2023 a May 2024